You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

166 Results
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Adjuvant
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Intent: Adjuvant
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Oct 2024
Regimen
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Funding:
Exceptional Access Program
    osimertinib - For adjuvant therapy after tumour resection in patients with stage IB-IIIA (AJCC 7th edition, or equivalent) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858 R) substitution mutations
Dec 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
May 2019
Regimen
Regimen
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Adjuvant
Dec 2017
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Curative, Adjuvant
Jan 2019
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Adjuvant, Curative
May 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant, Palliative
Jun 2019
Regimen
Intent: Adjuvant
Feb 2018

Pages